Logo image of SPRB

SPRUCE BIOSCIENCES INC (SPRB) Stock Fundamental Analysis

NASDAQ:SPRB - Nasdaq - US85209E1091 - Common Stock

0.3703  0 (-0.94%)

Fundamental Rating

1

Taking everything into account, SPRB scores 1 out of 10 in our fundamental rating. SPRB was compared to 572 industry peers in the Biotechnology industry. Both the profitability and financial health of SPRB have multiple concerns. SPRB does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

SPRB had negative earnings in the past year.
SPRB had a negative operating cash flow in the past year.
SPRB had negative earnings in each of the past 5 years.
SPRB had a negative operating cash flow in each of the past 5 years.
SPRB Yearly Net Income VS EBIT VS OCF VS FCFSPRB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -10M -20M -30M -40M -50M

1.2 Ratios

SPRB has a Return On Assets (-60.56%) which is in line with its industry peers.
With a Return On Equity value of -76.35%, SPRB perfoms like the industry average, outperforming 53.63% of the companies in the same industry.
Industry RankSector Rank
ROA -60.56%
ROE -76.35%
ROIC N/A
ROA(3y)-44.49%
ROA(5y)-86.02%
ROE(3y)-56%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SPRB Yearly ROA, ROE, ROICSPRB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 -1K -2K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SPRB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SPRB Yearly Profit, Operating, Gross MarginsSPRB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 -100 -200 -300 -400 -500

More info and screens

3

2. Health

2.1 Basic Checks

SPRB does not have a ROIC to compare to the WACC, probably because it is not profitable.
SPRB has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, SPRB has more shares outstanding
The debt/assets ratio for SPRB has been reduced compared to a year ago.
SPRB Yearly Shares OutstandingSPRB Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
SPRB Yearly Total Debt VS Total AssetsSPRB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -5.32, we must say that SPRB is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of SPRB (-5.32) is worse than 63.89% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that SPRB is not too dependend on debt financing.
The Debt to Equity ratio of SPRB (0.01) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -5.32
ROIC/WACCN/A
WACC11.34%
SPRB Yearly LT Debt VS Equity VS FCFSPRB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 50M 100M

2.3 Liquidity

A Current Ratio of 5.36 indicates that SPRB has no problem at all paying its short term obligations.
SPRB has a Current ratio (5.36) which is in line with its industry peers.
A Quick Ratio of 5.36 indicates that SPRB has no problem at all paying its short term obligations.
SPRB has a Quick ratio (5.36) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 5.36
Quick Ratio 5.36
SPRB Yearly Current Assets VS Current LiabilitesSPRB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 36.24% over the past year.
Looking at the last year, SPRB shows a decrease in Revenue. The Revenue has decreased by -1.38% in the last year.
EPS 1Y (TTM)36.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30%
Revenue 1Y (TTM)-1.37%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-80.41%

3.2 Future

Based on estimates for the next years, SPRB will show a small growth in Earnings Per Share. The EPS will grow by 3.48% on average per year.
SPRB is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -21.84% yearly.
EPS Next Y23.64%
EPS Next 2Y24.47%
EPS Next 3Y14.9%
EPS Next 5Y3.48%
Revenue Next Year-40.59%
Revenue Next 2Y-51.7%
Revenue Next 3Y-13.75%
Revenue Next 5Y-21.84%

3.3 Evolution

SPRB Yearly Revenue VS EstimatesSPRB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M
SPRB Yearly EPS VS EstimatesSPRB Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SPRB. In the last year negative earnings were reported.
Also next year SPRB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SPRB Price Earnings VS Forward Price EarningsSPRB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SPRB Per share dataSPRB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

SPRB's earnings are expected to grow with 14.89% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.47%
EPS Next 3Y14.9%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SPRB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SPRUCE BIOSCIENCES INC

NASDAQ:SPRB (1/22/2025, 11:47:32 AM)

0.3703

0 (-0.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-11 2024-11-11/bmo
Earnings (Next)N/A N/A
Inst Owners48.64%
Inst Owner Change0%
Ins Owners7.72%
Ins Owner Change2.63%
Market Cap15.29M
Analysts50.91
Price Target1.87 (405%)
Short Float %0.29%
Short Ratio0.17
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)23.04%
Min EPS beat(2)13.31%
Max EPS beat(2)32.77%
EPS beat(4)4
Avg EPS beat(4)22.56%
Min EPS beat(4)5.11%
Max EPS beat(4)39.07%
EPS beat(8)7
Avg EPS beat(8)16.48%
EPS beat(12)10
Avg EPS beat(12)14.24%
EPS beat(16)13
Avg EPS beat(16)13.53%
Revenue beat(2)1
Avg Revenue beat(2)-27.46%
Min Revenue beat(2)-60.5%
Max Revenue beat(2)5.57%
Revenue beat(4)3
Avg Revenue beat(4)29.19%
Min Revenue beat(4)-60.5%
Max Revenue beat(4)102.17%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-26.67%
PT rev (3m)-26.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)34.37%
EPS NY rev (1m)0%
EPS NY rev (3m)5.19%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)31.36%
Revenue NY rev (1m)3.01%
Revenue NY rev (3m)-18.1%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.15
P/FCF N/A
P/OCF N/A
P/B 0.3
P/tB 0.3
EV/EBITDA N/A
EPS(TTM)-0.95
EYN/A
EPS(NY)-0.57
Fwd EYN/A
FCF(TTM)-1.13
FCFYN/A
OCF(TTM)-1.13
OCFYN/A
SpS0.17
BVpS1.25
TBVpS1.25
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -60.56%
ROE -76.35%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-44.49%
ROA(5y)-86.02%
ROE(3y)-56%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.11
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 5.26%
Cap/Sales 0.04%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.36
Quick Ratio 5.36
Altman-Z -5.32
F-Score4
WACC11.34%
ROIC/WACCN/A
Cap/Depr(3y)50.95%
Cap/Depr(5y)65.57%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30%
EPS Next Y23.64%
EPS Next 2Y24.47%
EPS Next 3Y14.9%
EPS Next 5Y3.48%
Revenue 1Y (TTM)-1.37%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-80.41%
Revenue Next Year-40.59%
Revenue Next 2Y-51.7%
Revenue Next 3Y-13.75%
Revenue Next 5Y-21.84%
EBIT growth 1Y18.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-24.25%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-16.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-16.96%
OCF growth 3YN/A
OCF growth 5YN/A